High‐dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma

Raymond E. Lenhard; Martin M. Oken; Janet M. Barnes; Richard L. Humphrey; John H. Glick; Murray N. Silverstein

doi:10.1002/1097-0142(19840401)53:7<1456::AID-CNCR2820530705>3.0.CO;2-C

High‐dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma

Raymond E. Lenhard, Martin M. Oken, Janet M. Barnes, Richard L. Humphrey, John H. Glick, Murray N. Silverstein

School of Medicine

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

The Eastern Cooperative Oncology Group evaluated cyclophosphamide 600 mg/m² intravenously daily × 4 (total dose each cycle 2400 mg/m²) as an aggressive approach to the treatment of patients with advanced multiple myeloma. The overall objective response rate is 43%. This includes a 38% response rate for all previously treated patients and a 29% response rate for patients refractory to prior therapy with cyclophosphamide. The objective response duration was 3 months and the survival of responding patients 9 months. A subjective response rate of 63% was observed, characterized by effective pain relief and improved performance. Sixty‐nine percent of patients experienced leukocyte cell nadirs < 500/mm² with a mean time to marrow recovery of 17 days. Thrombocytopenia was less severe but required platelet transfusion in 43% of patients. Bone marrow toxicity was encountered in all patients, and death in aplasia is a significant risk. Strict adherence to entry criteria, and a systematic plan for hospitalization for antibiotic and blood component support is required for treatment with this regimen.

Original language	English (US)
Pages (from-to)	1456-1460
Number of pages	5
Journal	Cancer
Volume	53
Issue number	7
DOIs	https://doi.org/10.1002/1097-0142(19840401)53:7<1456::AID-CNCR2820530705>3.0.CO;2-C
State	Published - Apr 1 1984

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(19840401)53:7<1456::AID-CNCR2820530705>3.0.CO;2-C

Cite this

@article{dc16a662cb3a441486889aca6fee0c74,

title = "High‐dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma",

abstract = "The Eastern Cooperative Oncology Group evaluated cyclophosphamide 600 mg/m2 intravenously daily × 4 (total dose each cycle 2400 mg/m2) as an aggressive approach to the treatment of patients with advanced multiple myeloma. The overall objective response rate is 43%. This includes a 38% response rate for all previously treated patients and a 29% response rate for patients refractory to prior therapy with cyclophosphamide. The objective response duration was 3 months and the survival of responding patients 9 months. A subjective response rate of 63% was observed, characterized by effective pain relief and improved performance. Sixty‐nine percent of patients experienced leukocyte cell nadirs < 500/mm2 with a mean time to marrow recovery of 17 days. Thrombocytopenia was less severe but required platelet transfusion in 43% of patients. Bone marrow toxicity was encountered in all patients, and death in aplasia is a significant risk. Strict adherence to entry criteria, and a systematic plan for hospitalization for antibiotic and blood component support is required for treatment with this regimen.",

author = "Lenhard, {Raymond E.} and Oken, {Martin M.} and Barnes, {Janet M.} and Humphrey, {Richard L.} and Glick, {John H.} and Silverstein, {Murray N.}",

year = "1984",

month = apr,

day = "1",

doi = "10.1002/1097-0142(19840401)53:7<1456::AID-CNCR2820530705>3.0.CO;2-C",

language = "English (US)",

volume = "53",

pages = "1456--1460",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "7",

}

TY - JOUR

T1 - High‐dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma

AU - Lenhard, Raymond E.

AU - Oken, Martin M.

AU - Barnes, Janet M.

AU - Humphrey, Richard L.

AU - Glick, John H.

AU - Silverstein, Murray N.

PY - 1984/4/1

Y1 - 1984/4/1

N2 - The Eastern Cooperative Oncology Group evaluated cyclophosphamide 600 mg/m2 intravenously daily × 4 (total dose each cycle 2400 mg/m2) as an aggressive approach to the treatment of patients with advanced multiple myeloma. The overall objective response rate is 43%. This includes a 38% response rate for all previously treated patients and a 29% response rate for patients refractory to prior therapy with cyclophosphamide. The objective response duration was 3 months and the survival of responding patients 9 months. A subjective response rate of 63% was observed, characterized by effective pain relief and improved performance. Sixty‐nine percent of patients experienced leukocyte cell nadirs < 500/mm2 with a mean time to marrow recovery of 17 days. Thrombocytopenia was less severe but required platelet transfusion in 43% of patients. Bone marrow toxicity was encountered in all patients, and death in aplasia is a significant risk. Strict adherence to entry criteria, and a systematic plan for hospitalization for antibiotic and blood component support is required for treatment with this regimen.

AB - The Eastern Cooperative Oncology Group evaluated cyclophosphamide 600 mg/m2 intravenously daily × 4 (total dose each cycle 2400 mg/m2) as an aggressive approach to the treatment of patients with advanced multiple myeloma. The overall objective response rate is 43%. This includes a 38% response rate for all previously treated patients and a 29% response rate for patients refractory to prior therapy with cyclophosphamide. The objective response duration was 3 months and the survival of responding patients 9 months. A subjective response rate of 63% was observed, characterized by effective pain relief and improved performance. Sixty‐nine percent of patients experienced leukocyte cell nadirs < 500/mm2 with a mean time to marrow recovery of 17 days. Thrombocytopenia was less severe but required platelet transfusion in 43% of patients. Bone marrow toxicity was encountered in all patients, and death in aplasia is a significant risk. Strict adherence to entry criteria, and a systematic plan for hospitalization for antibiotic and blood component support is required for treatment with this regimen.

UR - http://www.scopus.com/inward/record.url?scp=0021349078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021349078&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19840401)53:7<1456::AID-CNCR2820530705>3.0.CO;2-C

DO - 10.1002/1097-0142(19840401)53:7<1456::AID-CNCR2820530705>3.0.CO;2-C

M3 - Article

C2 - 6697291

AN - SCOPUS:0021349078

SN - 0008-543X

VL - 53

SP - 1456

EP - 1460

JO - Cancer

JF - Cancer

IS - 7

ER -

High‐dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this